Deucravacitinib Therapeutic Cheat Sheet
Psoriasis is one of the most common immune-mediated inflammatory dermatoses, with increasing evidence for systemic comorbidities. Targeted systemic agents have revolutionized the management of moderate-to-severe psoriasis, with life-changing outcomes for many patients with the chronic disease. Injectable biologics, blocking interleukin (IL)-23 or IL-17 cytokine pathways, have become invaluable opt …
Psoriasis is one of the most common immune-mediated inflammatory dermatoses, with increasing evidence for systemic comorbidities. Targeted systemic agents have revolutionized the management of moderate-to-severe psoriasis, with life-changing outcomes for many patients with the chronic disease. Injectable biologics, blocking interleukin (IL)-23 or IL-17 cytokine pathways, have become invaluable opt …
Pretibial myxedema (PTM) is a rare complication of Graves' disease. It is characterized by non-pitting edema with hyperpigmented hyperkeratotic papules and plaques on bilateral lower legs. Effective treatments for patients with PTM are lacking. The etiology of PTM is unknown; however, it may be similar to the mechanism of thyroid-associated ophthalmopathy (TAO). Activated fibroblasts produce infla …
Next Steps in Derm, in partnership with Pigmentary Disorders Exchange Symposium interviewed Dr. Amit Pandya, staff dermatologist with Palo Alto Foundation Medical Group and adjunct professor in the department of dermatology at the University of Texas Southwestern Medical Center. Dr. Pandya says this is the most exciting time for him as a dermatologist with new vitiligo medications on the market an …
Next Steps in Derm, in partnership with ODAC Dermatology, Aesthetic & Surgical Conference, interviewed Dr. Terrance Keaney, assistant clinical faculty of dermatology at GW School of Medicine and Health Sciences, and Howard University. Dr. Keaney says there’s more to neuromodulators than the active protein -- other proteins in the vials could play a role in treatment effectiveness. Could eve …